Published: 29 November 2023
Committees
Agenda for the 196th meeting of the Medicines Adverse Reactions Committee to be held on Thursday 7 December 2023, at 9 am
1. |
MATTERS OF ADMINISTRATION |
1.1 |
Welcome and apologies |
1.2 |
Minutes and recommendations of the 195th MARC meeting |
1.3 |
Declarations of potential competing interests |
2. |
MATTERS ARISING FROM THE NZ PHARMACOVIGILANCE CENTRE |
2.1 |
CARM quarterly report |
3. |
PHARMACOVIGILANCE REPORTS |
3.1 |
Matters referred to the MARC under section 36 of the Medicines Act 1981 |
|
No items |
3.2 |
Matters referred to the MARC by Medsafe |
|
3.2.1 Direct-acting oral anticoagulants (DOACs) and anticoagulant-related nephropathy (ARN) |
|
3.2.2 Potential drug interaction between estrogen-based hormone replacement therapy and lamotrigine |
|
3.2.3 Third generation aromatase inhibitors and tendon disorders |
|
3.2.4 Tumour lysis syndrome with tyrosine kinase inhibitors and monoclonal antibodies when used in cancer treatment |
4. |
MEDSAFE PHARMACOVIGILANCE ACTIVITIES |
4.1 |
Report on standing agenda items |
4.2 |
Medsafe pharmacovigilance activities |
4.3 |
Prescriber Update |
4.4 |
Quarterly summary of recent safety communications |